Improving the effectiveness of HIV medications through new drug formulations
Official title: Ionic Liquids of tenofovir prodrugs for improved oral bioavailability and antiviral efficacy
Funded at University of Arizona · NIH-10913330 · Data updated 2026-11-12
This study is looking at new ways to make HIV medications work better in your body by changing them into a special form that helps them absorb more easily, so you can get the right dose with fewer side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Arizona NIH-funded |
| Lab location | 1 site (Tucson, United States) |
| Project start | August 24, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $206,452 |
| NIH project number | 5R21AI176907-02 |
| Project ID | NIH-10913330 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are currently on antiretroviral therapy.
✕Less likely to help
Patients who are not living with HIV or those who are not on antiretroviral therapy may not benefit from this research.
What this research studies
This research focuses on enhancing the oral bioavailability of tenofovir prodrugs, which are essential in treating HIV/AIDS. The approach involves transforming these drugs into ionic liquids to improve their absorption and effectiveness in the body. By using innovative methods to package these drugs into nanomicelles, the research aims to ensure that patients receive optimal therapeutic doses with fewer side effects. This could lead to more effective long-term treatment options for individuals living with HIV.
Why it matters
Potential benefit: If successful, this research could lead to more effective and better-tolerated HIV treatments for patients.
How similar studies have gone: Other research has shown promise in using ionic liquids to enhance drug delivery, suggesting that this approach could be effective.
Where this research is happening
-
University of Arizona
Tucson, United States Active
Researchers
- Principal investigator: Date, Abhijit a — University of Arizona
- Study coordinator: Date, Abhijit a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.